Literature DB >> 32030270

Does an imbalance in circulating vascular endothelial growth factors (VEGFs) cause atrial fibrillation in patients with valvular heart disease?

Keke Wang1,2, Yanyan Liu3, Suiqing Huang1,4, Huayang Li1, Jian Hou1,4, Jiaxing Huang1, Jiantao Chen1, Kangni Feng1, Mengya Liang1, Guangxian Chen1, Zhongkai Wu1,4.   

Abstract

BACKGROUND: The pathogenesis of atrial fibrillation (AF) remains unclear. Vascular endothelial growth factors (VEGFs) can stimulate fibrosis within the atrium and ventricle. We hypothesized that there is a relationship between the serum VEGFs/soluble vascular endothelial growth factor receptor (sVEGFRs) levels and AF in patients with valvular heart disease (VHD). This provides a new paradigm for studying AF.
METHODS: The plasma levels of VEGF-A, VEGF-C, sVEGFR-1 and sVEGFR-2 were detected by enzyme-linked immunosorbent assay (ELISA). A total of 100 people, consisting of AF patients (long-standing, persistent AF; n=49), sinus rhythm (SR) patients (n=31) and healthy controls (n=20), were included in this study.
RESULTS: The plasma levels of VEGF-A were significantly higher in AF patients compared to healthy control (P<0.05). The plasma levels of sVEGFR-1 were significantly higher in AF compared to SR (P<0.05). The plasma levels of sVEGFR-2 were significantly lower in AF patients compared to SR patients and healthy controls (both P<0.05). There was a significant and negative correlation between AF and the sVEGFR-2 levels in the groups (r=-0.432, P=0.000).
CONCLUSIONS: An imbalance in VEGFs and sVEGFRs may contribute to AF by breaking the balance of angiogenesis and lymphangiogenesis. Additionally, sVEGFR-2 may be an important biomarker of AF. 2019 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation (AF); soluble vascular endothelial growth factor receptor-1 (sVEGFR-1); soluble vascular endothelial growth factor receptor-2 (sVEGFR-2); vascular endothelial growth factor-A (VEGF-A); vascular endothelial growth factor-C (VEGF-C)

Year:  2019        PMID: 32030270      PMCID: PMC6988013          DOI: 10.21037/jtd.2019.11.32

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  45 in total

1.  Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation.

Authors:  Alina Scridon; Elodie Morel; Emilie Nonin-Babary; Nicolas Girerd; Carmen Fernandez; Philippe Chevalier
Journal:  Europace       Date:  2012-02-02       Impact factor: 5.214

Review 2.  Microparticles in atrial fibrillation: a link between cell activation or apoptosis, tissue remodelling and thrombogenicity.

Authors:  L Jesel; M Abbas; F Toti; A Cohen; T Arentz; O Morel
Journal:  Int J Cardiol       Date:  2013-04-23       Impact factor: 4.164

Review 3.  Atrial fibrillation compendium: historical context and detailed translational perspective on an important clinical problem.

Authors:  Kunihiro Nishida; Stanley Nattel
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 4.  Modifiable Risk Factors and Atrial Fibrillation.

Authors:  Dennis H Lau; Stanley Nattel; Jonathan M Kalman; Prashanthan Sanders
Journal:  Circulation       Date:  2017-08-08       Impact factor: 29.690

5.  Atrial fibrillation impairs endothelial function of forearm vessels in humans.

Authors:  N Takahashi; Y Ishibashi; T Shimada; T Sakane; S Ohata; T Sugamori; Y Ohta; S Inoue ; K Nakamura; H Shimizu; H Katoh; K Sano; Y Murakami; M Hashimoto
Journal:  J Card Fail       Date:  2001-03       Impact factor: 5.712

6.  Autocrine regulation of myocyte Cx43 expression by VEGF.

Authors:  Rhea C Pimentel; Kathryn A Yamada; André G Kléber; Jeffrey E Saffitz
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

7.  Distinct pathways regulate expression of cardiac electrical and mechanical junction proteins in response to stretch.

Authors:  Kiyomi Yamada; Karen G Green; Allen M Samarel; Jeffrey E Saffitz
Journal:  Circ Res       Date:  2005-07-21       Impact factor: 17.367

8.  The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model.

Authors:  Masa-Aki Shibata; Jayakrishna Ambati; Eiko Shibata; Romulo J C Albuquerque; Junji Morimoto; Yuko Ito; Yoshinori Otsuki
Journal:  BMC Med       Date:  2010-11-03       Impact factor: 8.775

9.  Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.

Authors:  Tuomas Tammela; Georgia Zarkada; Elisabet Wallgard; Aino Murtomäki; Steven Suchting; Maria Wirzenius; Marika Waltari; Mats Hellström; Tibor Schomber; Reetta Peltonen; Catarina Freitas; Antonio Duarte; Helena Isoniemi; Pirjo Laakkonen; Gerhard Christofori; Seppo Ylä-Herttuala; Masabumi Shibuya; Bronislaw Pytowski; Anne Eichmann; Christer Betsholtz; Kari Alitalo
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

10.  All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study.

Authors:  Tommy Andersson; Anders Magnuson; Ing-Liss Bryngelsson; Ole Frøbert; Karin M Henriksson; Nils Edvardsson; Dritan Poçi
Journal:  Eur Heart J       Date:  2013-01-14       Impact factor: 29.983

View more
  4 in total

Review 1.  Atrial fibrillation: the role of hypoxia-inducible factor-1-regulated cytokines.

Authors:  Savalan Babapoor-Farrokhran; Deanna Gill; Jafar Alzubi; Sumeet K Mainigi
Journal:  Mol Cell Biochem       Date:  2021-02-11       Impact factor: 3.396

2.  Correlation analysis of survivin, ING4, CXCL8 and VEGF expression in prostate cancer tissue.

Authors:  Lingwei Kong; Rushan Qi; Guangchun Zhou; Sentai Ding
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  Mechanisms of Quercetin against atrial fibrillation explored by network pharmacology combined with molecular docking and experimental validation.

Authors:  Xin Tan; Wei Xian; Xiaorong Li; Yongfeng Chen; Jiayi Geng; Qiyi Wang; Qin Gao; Bi Tang; Hongju Wang; Pinfang Kang
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

4.  Antibody microarray analysis of serum inflammatory cytokines in patients with calcific aortic valve disease.

Authors:  Bo Fu; Yuhui Zhang; Qingliang Chen; Zhigang Guo; Nan Jiang
Journal:  Ann Transl Med       Date:  2020-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.